Medpage Today on MSN3d
Nipocalimab Shows Sustained Efficacy in Myasthenia GravisInvestigational nipocalimab lessened disease severity in generalized myasthenia gravis (gMG), the phase III Vivacity-MG3 ...
A first-in-class anti-CD19 B-cell depleting agent was safe and demonstrated superior efficacy vs placebo in patients with ...
The investigational monoclonal antibody nipocalimab is associated with significant improvement in patients with generalized ...
Johnson & Johnson has burnished the evidence for nipocalimab, adding a sliver of data in adolescents with generalized ...
MedPage Today on MSN3d
Anti-CD19 Monoclonal Antibody Shows Positive Results in Myasthenia Gravis"Inebilizumab is a humanized monoclonal antibody that causes targeted and sustained depletion of CD19-positive B cells, ...
Actor-filmmaker Tinnu Anand recently opened up about the time when megastar Amitabh Bachchan was diagnosed with myasthenia ...
Tuesday announced positive topline data from the Phase 3 MINT study evaluating Uplizna for the treatment of adults ...
Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the ...
Amgen said it achieved positive results from a Phase 3 trial of its treatment for adults with generalized myasthenia gravis, a rare autoimmune disorder.
QMG (Quantitative Myasthenia Gravis) is a 13-item assessment by a clinician that quantifies MG disease severity through muscle weakness. The total QMG score ranges from 0 to 39, where higher scores ...
The potential value of these biomarkers may help differentiate acetylcholine receptor antibody seropositive (AChR+) myasthenia gravis (MG) from healthy patients. If integrated into clinical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback